Related Experiment Videos
[Hypertension after kidney transplantation].
1II. vnitrní klinika Fakultní nemocnice U sv. Anny, Brno.
Vnitrni Lekarstvi
|August 22, 2000
Summary
Hypertension is a common complication after kidney transplants, often linked to immunosuppressive drugs like corticoids, cyclosporin A, and mycophenolate mofetil. This study tracked its incidence and management in transplant recipients.
Area of Science:
- Nephrology
- Transplantation Medicine
- Cardiovascular Medicine
Background:
- Hypertension is a frequent complication post-kidney transplantation, affecting over 60% of recipients.
- While hypervolemia is key in dialysis patients, immunosuppressive drugs are primary drivers post-transplant.
- This study focuses on hypertension in patients treated with corticoids, cyclosporin A (CyA), and mycophenolate mofetil (MFM).
Purpose of the Study:
- To assess the incidence of hypertension one and two years post-kidney transplantation.
- To evaluate blood pressure (BP) levels and hypertension management strategies.
- To analyze hypertension in recipients on corticoids, CyA, and MFM immunosuppression.
Main Methods:
- The study included 58 recipients of cadaverous renal grafts (35 men, 23 women).
- Blood pressure was measured via auscultation during regular ambulatory follow-ups.
- Hypertension was defined as BP > 130/85 mm Hg or a mean arterial pressure (MAP) > 100 mm Hg.
Main Results:
- The study involved 58 kidney graft recipients, with 91.4% receiving their first graft.
- Blood pressure was monitored regularly, with hypertension defined by specific BP or MAP thresholds.
- Data on BP levels and therapeutic interventions were collected for the first and second year post-transplant.
Conclusions:
- Immunosuppressive therapy, including corticoids, CyA, and MFM, is a significant factor in post-transplant hypertension.
- Regular BP monitoring and management are crucial for kidney transplant recipients.
- Further research is needed to optimize hypertension control in this population.